The Journal of Pediatrics
Volume 153, Issue 1 , Pages 89-94.e4 , July 2008

Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease

  • Ozlem Goker-Alpan, MD

      Affiliations

    • Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD
    • ,
  • Edythe A. Wiggs, PhD

      Affiliations

    • Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD.
    • ,
  • Michael J. Eblan, BA

      Affiliations

    • Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD
    • ,
  • William Benko, MD

      Affiliations

    • Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD.
    • ,
  • Shira G. Ziegler

      Affiliations

    • Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD
    • ,
  • Ellen Sidransky, MD

      Affiliations

    • Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD
    • Corresponding Author InformationReprint requests: Ellen Sidransky, MD, Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, Building 35, Room 1A213, 35 Convent Dr, MSC 3708, Bethesda, MD 20892-3708.
    • ,
  • Raphael Schiffmann, MD

      Affiliations

    • Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD.

Received 30 March 2007 ,Revised 23 October 2007 ,Accepted 10 December 2007.

References 

  1. Leth P, Knudsen IM. Gaucher's disease. Ugeskr Laeger. 1987;149:1515–1519
  2. Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr. 2003;143:273–276
  3. Beutler E, Grabowski GA. Gaucher disease. In:  Scriver CR,  Beudet AL,  Valle D,  Sly WS editor. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001;p. 3635–3668
  4. Schiffmann R, Brady RO. New prospects for the treatment of lysosomal storage diseases. Drugs. 2002;62:733–742
  5. Sidransky E, Tsuji S, Stubblefield BK, Currie J, FitzGibbon EJ, Ginns EI. Gaucher patients with oculomotor abnormalities do not have a unique genotype. Clin Genet. 1992;41:1–5
  6. Patterson MC, Horowitz M, Abel RB, Currie JN, Yu KT, Kaneski C, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. Neurology. 1993;43:1993–1997
  7. Park JK, Orvisky E, Tayebi N, Kaneski C, LaMarca ME, Stubblefield BK, et al. Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr Res. 2003;53:387–395
  8. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324:1464–1470
  9. Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, et al. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. Lancet. 1994;344:1679–1682
  10. Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK, Schiffmann R, et al. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet. 2005;42:e37
  11. Tayebi N, Reissner K, Lau EK, Stubblefield BK, Klineburgess AC, Martin BM, et al. Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher's disease. Pediatr Res. 1998;43:571–578
  12. Tayebi N, Cushner S, Sidransky E. Differentiation of the glucocerebrosidase gene from pseudogene by long-template PCR: implications for Gaucher disease. Am J Hum Genet. 1996;59:740–741
  13. Lichtenberger EO. General measures of cognition for the preschool child. Ment Retard Dev Disabil Res Rev. 2005;11:197–208
  14. Wechsler D. Wechsler Intelligence Scale for Children-Fourth Edition: Administration and scoring manual. San Antonio: The Psychological Corporation; 2003;
  15. Wechsler D. Wechsler Adult Intelligence Scale-Third Edition: Administration and scoring manual. San Antonio: The Psychological Corporation; 1997;
  16. Theodoropoulos DS, Krasnewich D, Kaiser-Kupfer MI, Gahl WA. Classic nephropathic cystinosis as an adult disease. JAMA. 1993;270:2200–2204
  17. Klinge L, Straub V, Neudorf U, Voit T. Enzyme replacement therapy in classical infantile Pompe disease: results of a ten-month follow-up study. Neuropediatrics. 2005;36:6–11
  18. Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker C, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr. 2001;138:539–547
  19. Erikson A, Karlberg J, Skogman AL, Dreborg S. Gaucher disease (type III): intellectual profile. Pediatr Neurol. 1987;3:87–91
  20. Erikson A. Gaucher disease-Norrbottnian type (III) (Neuropaediatric and neurobiological aspects of clinical patterns and treatment). Acta Paediatr Scand Suppl. 1986;326:1–42
  21. Huttenlocher PR, Dabholkar AS. Regional differences in synaptogenesis in human cerebral cortex. J Comp Neurol. 1997;387:167–178
  22. Garvey MA, Toro C, Goldstein S, Altarescu G, Wiggs EA, Hallett M, et al. Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease. Neurology. 2001;56:391–394
  23. Krei KP, Schiffmann R. Myoclonus in Gaucher disease. Adv Neurol. 2002;89:41–48
  24. Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav. 2003;4(Suppl 2):S25–S38
  25. Elger CE, Halmstaeder C, Kurthen M. Chronic epilepsy and cognition. Lancet Neurol. 2004;3:663–672
  26. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192–207
  27. Elstein D, Guedalia J, Doniger GM, Simon ES, Antebi V, Arnon Y, et al. Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction. Genet Med. 2005;7:124–130
  28. Brambilla P, Hardan A, di Nemi SU, Perez J, Soares JC, Barale F. Brain anatomy and development in autism: review of structural MRI studies. Brain Res Bull. 2003;61:557–569

 Supported by the Intramural Programs of the National Institute of Neurological Disorders and Stroke and the National Human Genome Research Institute.

PII: S0022-3476(07)01169-9

doi: 10.1016/j.jpeds.2007.12.023

The Journal of Pediatrics
Volume 153, Issue 1 , Pages 89-94.e4 , July 2008

Article Tools

* Image Usage & Resolution